​

Akero Therapeutics (AKRO) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

AKRO Stock Forecast

Akero Therapeutics (AKRO) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $54.67, with a high of $56.00 and a low of $54.00. This represents a 1.24% increase from the last price of $54.00.

$15 $24 $33 $42 $51 $60 High: $56 Avg: $54.67 Low: $54 Last Closed Price: $54

AKRO Stock Rating

Akero Therapeutics stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (71.43%), 4 Hold (28.57%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 4 10 Strong Sell Sell Hold Buy Strong Buy

AKRO Price Target Upside V Benchmarks

TypeNameUpside
StockAkero Therapeutics1.24%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts344
Avg Price Target$54.67$59.00$59.00
Last Closing Price$54.00$54.00$54.00
Upside/Downside1.24%9.26%9.26%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2538---11
Sep, 25210---12
Aug, 2529---11
Jul, 2529---11
Jun, 2529---11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 10, 2025H.C. Wainwright$54.00$54.08-0.15%-
Oct 09, 2025Jefferies$56.00$54.153.42%3.70%
Oct 09, 2025Canaccord Genuity$54.00$54.19-0.35%-
Sep 04, 2025Andrew FeinH.C. Wainwright$72.00$45.6257.83%33.33%
Sep 17, 2024Ed ArceH.C. Wainwright$50.00$26.9785.39%-7.41%
Jun 12, 2024Edward NashCanaccord Genuity$56.00$23.43139.01%3.70%
Jun 10, 2024Andy ChenWolfe Research$40.00$22.9973.99%-25.93%
May 15, 2024Liisa BaykoEvercore ISI$38.00$20.3087.19%-29.63%
Oct 11, 2023Ed ArceH.C. Wainwright$40.00$15.04165.96%-25.93%
Sep 13, 2022Liisa BaykoEvercore ISI$50.00$29.0572.12%-7.41%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 10, 2025H.C. WainwrightBuyNeutraldowngrade
Oct 09, 2025JefferiesHolddowngrade
Aug 04, 2025Cowen & Co.Buyinitialise
Mar 02, 2025Morgan StanleyOverweightOverweighthold
Feb 02, 2025BarclaysOverweightupgrade
Nov 18, 2024CitigroupBuyinitialise
Sep 17, 2024H.C. WainwrightBuyBuyhold
Jun 12, 2024Canaccord GenuityBuyBuyhold
Jun 10, 2024Wolfe ResearchOutperforminitialise
May 15, 2024Evercore ISIOutperformOutperformhold

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.89$-3.75----
Avg Forecast$-2.77$-4.04$-4.75$-4.70$-2.71$-1.08
High Forecast$-2.62$-3.89$-4.49$-4.25$-1.17$-1.08
Low Forecast$-3.07$-4.32$-5.06$-5.04$-4.25$-1.08
Surprise %4.33%-7.18%----

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$4.30M$58.02M$217.28M
High Forecast---$4.30M$58.02M$217.28M
Low Forecast---$4.30M$58.02M$217.28M
Surprise %------

Net Income Forecast

$-300M $-250M $-200M $-150M $-100M $-50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-151.76M$-252.06M----
Avg Forecast$-151.76M$-215.91M$-251.13M$-244.11M$-210.53M$-56.51M
High Forecast$-137.53M$-204.74M$-236.16M$-223.53M$-61.50M$-56.51M
Low Forecast$-161.32M$-227.08M$-266.09M$-264.69M$-223.41M$-56.51M
Surprise %-16.74%----

AKRO Forecast FAQ

Is Akero Therapeutics stock a buy?

Akero Therapeutics stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Akero Therapeutics is a favorable investment for most analysts.

What is Akero Therapeutics's price target?

Akero Therapeutics's price target, set by 14 Wall Street analysts, averages $54.67 over the next 12 months. The price target range spans from $54 at the low end to $56 at the high end, suggesting a potential 1.24% change from the previous closing price of $54.

How does Akero Therapeutics stock forecast compare to its benchmarks?

Akero Therapeutics's stock forecast shows a 1.24% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Akero Therapeutics over the past three months?

  • October 2025: 27.27% Strong Buy, 72.73% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 18.18% Strong Buy, 81.82% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Akero Therapeutics’s EPS forecast?

Akero Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-4.75, marking a 26.67% increase from the reported $-3.75 in 2024. Estimates for the following years are $-4.7 in 2026, $-2.71 in 2027, and $-1.08 in 2028.

What is Akero Therapeutics’s revenue forecast?

Akero Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $4.3M, followed by $58.02M for 2027, and $217.28M for 2028.

What is Akero Therapeutics’s net income forecast?

Akero Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-251M, representing a -0.37% decrease from the reported $-252M in 2024. Projections indicate $-244M in 2026, $-211M in 2027, and $-56.511M in 2028.